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Was to evaluate whether a person’s beliefs regarding
where control over his health lies impacts his level of
compliance. METHOD: Data were collected on 460
DVA hyperlipidemia patients in a multisite DVA phar-
maceutical care study. Patients were given Form C of the
Multidimensional Health Locus of Control (MHLC).
Form C is an 18 item general purpose, condition-specific
locus of control scale consisting of 3 sub-scales, internal/
external control, chance and powerful others. Patients
were also given the Moriski Compliance Questionnaire
at visits 1, 5 and 7, and re-fill patterns were evaluated as
measures of compliance. RESULTS: Form C explains
16.1% of the variance in compliance (R2  0.161; P 
0.05). The internal/external control subscale R2  0.017;
P  0.05; the chance subscale R2  0.025; P  0.05; and
the powerful other subscale R2  0.155; P  0.001.
CONCLUSION: It is not surprising that the chance sub-
scale played little or no role in explaining the variance in
compliance, however we did expect the internal/external
control subscale to explain part of the variance. This
leads us to question whether the empowerment of pa-
tients improves compliance. Certainly, the impact of the
powerful others subscale suggests the opposite to be the
case. Patients with a high level of “powerful other” con-
trol were more likely to be compliant.
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Studies have demonstrated that subspecialists (SUBS)
provide better quality care when working within their
subspecialty as compared to primary care physicians
(PCPs). However, many SUBS care for patients outside of
their subspecialty. There are no data demonstrating that
SUBS treating patients outside of their specialty provide
worse care than PCPs or SUBS practicing within their
specialty. OBJECTIVES: Our purpose was to compare
the quality of care provided by SUBS practicing outside
of their subspecialty with PCPs and SUBS practicing
within their subspecialty. METHODS: We studied 5112
patients hospitalized with pneumonia (CAP), acute myo-
cardial infarction (AMI), congestive heart failure (CHF),
and upper gastrointestinal hemorrhage (UGIB) at 6 hos-
pitals in Cleveland. RESULTS: There were statistically
significant increases in severity-adjusted length of stay
(LOS) comparing SUBS practicing outside of specialty
with those practicing within specialty for patients with
CHF (23% increase, 95% CI 15%,32%), UGIB (22% in-
crease, 95% CI 7%,39%) and CAP (14% increase, 95%
CI 4%,24%). Severity-adjusted mortality (MORT) was
higher for all patients combined when comparing SUBS
outside of specialty with those within specialty (mortality
odds ratio 1.46, P  0.05). When comparing PCPs with
SUBs practicing outside of specialty, LOS was longer for
SUBs practicing outside of specialty for CHF (16% in-
crease, 95% CI 8%,26%), UGIB (15% increase, 95% CI
2%,30%), CAP (18% increase, 95% CI 9%,28%).
CONCLUSIONS: Our data suggest that SUBS caring for
patients outside of their subspecialty may have longer
LOS than SUBS practicing within specialty or PCPs, and
may have higher MORT. Our findings have implications
for health care systems where SUBS care for patients out-
side of their chosen subspecialty.
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OBJECTIVES: Most pharmacoeconomic studies concen-
trate mainly on drug costs and possibly, some additional
costs encountered in drug delivery when analysing over-
all hospital costs. Examination costs are mainly ignored
or, at best, estimated crudely. A flat rate is usually ap-
plied when calculating total therapy costs in hospitals.
METHODS: In this study, the total therapy costs of five
in-house non-surgical ENT treatments (30 patients in
each group) were calculated, with particular attention to
accurate personnel costing. Drug costs and examination
costs were examined independently. RESULTS: The total
therapy costs varied from $816 to $1562. Daily costs
varied from $170 to $186. Both examination costs and
drug costs were noted to amount to 25—28% of the total
therapy costs, but individual treatment analysis showed
wide variations in their relative contributions. For in-
stance in complicated otitis media examination costs
amounted 14.7% as compared to drug costs of 11.4%.
In contrast, in the treatment of sudden deafness, medica-
tion costs accounted for 2.5% of overall costs versus
24.6% of examination costs. CONCLUSIONS: Physi-
cians with cost responsibilities should be aware of the
differing contributions to overall costs from drug and ex-
amination costs. In detailed analysis, the relative contri-
butions from drug and examination costs can vary widely
but in our current study, the overall contribution from
these two categories was quite similar. Physicians should
be aware of the cost structure in different therapies so
that advantage may be taken of potential cost savings.
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BACKGROUND: The costs of interferon beta are high
(£10,000/patient year). The impact on health status and
quality of life is uncertain. These factors, plus limited
funding, restrictive indications and guidance for use
mean prescribing in the UK is low and variable. To ad-
dress these issues, a trial of interferon beta was proposed.
The research costs of the trial were substantial (£10.3
million). The treatment and support costs of the trial
could be in the region of £75 million. OBJECTIVES: To
assess the potential impact of the trial on the costs and
benefits of treatment for people with multiple sclerosis
(MS). METHODS: The evaluation compared the poten-
tial use, costs and QALYs of interferon beta, azathio-
prine and usual care with and without the trial. Decision
analysis was used to estimate the expected costs and
quality adjusted life years (QALYs) in two situations
with the trial: (i) the treatment with the highest QALY is
used; (ii) treatment decisions are made on efficiency crite-
ria (expected costs and QALYs). RESULTS: If treatment
decisions were made to maximise QALYs, the expected
cost and QALYs of the trial were between £3,026,000,000
and £3,904,000,000 and between 5,551 and 14,012 re-
spectively. The expected cost/QALY gained was between
£0–£369,000. Treatment decisions made on efficiency
criteria were associated with expected costs and QALYs
of between £8,292,000,000 and £167,000,000 and be-
tween 5355 and 14,969 respectively. The expected
cost/QALY lost was between £0–£662,728. CONCLU-
SIONS: The expected value of the trial depends upon the
decision-making criteria used and impact of the trial on
treatment decisions. If the trial leads to adoption of treat-
ments with a net cost/QALY less than £100,000, it
would lead to long term savings in the costs of care, but
losses of 251–5355 QALYs in the MS population.
PDH11
EVALUATION OF CIGARETTE SMOKER’S 
PERCEPTIONS OF SMOKING CESSATION 
AND THE ROLE OF HEALTH 
CARE PROFESSIONALS
Dodd MA, Gupchup GV
New Mexico Medicaid Retrospective Drug Utilization Review 
Program, College of Pharmacy, The University of New Mexico, 
Albuquerque, NM, USA
Cigarette smoking is a known cause of morbidity and
mortality and is associated with 400,000 deaths in the
United States annually. The guidelines released by the
Agency for Health Care Policy and Research (AHCPR)
encourages all clinicians to promote smoking cessation.
OBJECTIVES: To determine cigarette smokers’ knowl-
edge and use of smoking cessation aides and determine if
health care professionals have encouraged patients to
quit smoking cigarettes. METHODS: A survey instru-
ment was mailed in April 1999 with two reminder mail-
ings to 204 adult patients with a diagnosis of tobacco
abuse (ICD-9 code 305.1) in a Medicaid claims database.
RESULTS: Seventy-one of the 181 (39%) deliverable sur-
veys were returned. Seventy-three percent of the respon-
dents started smoking cigarettes at an age less than 18.
Fifty-nine percent of the patients have quit smoking at
least once, but 63% of the patients are currently smok-
ing. The majority of the patients who have quit at least
once (51%) did not use the assistance of smoking cessa-
tion medication. When the patients were asked regarding
who had asked them about their smoking habits, 72%
responded a physician had asked them, 48% responded a
health care professional besides a pharmacist, while only
17% responded that a pharmacist had asked them about
their smoking habits. CONCLUSIONS: Based on the re-
sults of this survey, many cigarette smokers start at a
young age. Additional societal education is needed re-
garding the risks of smoking and smoking cessation
methods. Furthermore, pharmacists need to be more in-
volved in promoting smoking cessation.
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The ultimate goal of pharmaceutical care is to improve
patient’s quality of life (QOL) by maximizing the benefits
and limiting the risks associated with medication ther-
apy. OBJECTIVE: To examine changes in QOL scores
for Veteran patients receiving pharmaceutical care from
clinical pharmacists. METHODS: This study was a pro-
spective multi-site randomized controlled trial of ambula-
tory care clinical pharmacists’ interventions for Veterans
Affairs patients who were at high-risk for drug-related
problems. Health related quality of life was assessed via
the short form 36-item (SF-36) questionnaire. The SF-36
questionnaire was administered to patients in treatment
and control groups at enrollment, 6 and 12 months. Con-
trol patients received usual medical care and intervention
patients were assigned to clinical pharmacists for consul-
tation and follow-up care. RESULTS: A total of 1054 pa-
tients were enrolled from 9 sites, 523 were randomized to
the intervention group and 531 to the control group.
Nine hundred fifty patients completed 6-month question-
naires and 931 completed the study. Clinical pharmacists
had 1855 contacts with intervention patients. The mean
number of contacts was 3.5  2.3. The group time inter-
action term was significant for the general health percep-
tions (GHP) and vitality domains. The average GHP
score declined 1.7 units for intervention patients com-
pared to 5.1 units for control patients (P  0.0066). Vi-
tality scores declined 1.3 units for intervention and 4.2
units for control patients (P  0.0034). CONCLU-
SIONS: The findings indicate ambulatory clinical phar-
macists had a statistical, but not clinically meaningful, ef-
